文献速递肝病

直接抗病毒药物治疗1型丙型肝炎病毒感染的有效性、安全性和临床结局:西班牙真实世界队列研究结果

Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
PubMed 文献 · J Hepatol · 2017-02-09

西班牙35个中心2015年4月1日至2016年2月28日纳入1型丙型肝炎病毒(HCV)感染患者,分别接受奥比他韦/帕利瑞韦/利托那韦联合达沙布韦(OMV/PTV/r+DSV)±利巴韦林(RBV)(n=1567)或雷迪帕韦/索磷布韦(LDV/SOF)±RBV(n=1758)治疗。两方案持续病毒学应答12周(SVR12)率分别为96.8%和95.8%,严重不良事件(SAE)率分别为5.4%和5.5%。

要点

  • OMV/PTV/r+DSV±RBV的SVR12率为96.8%,LDV/SOF±RBV为95.8%。
  • SAE发生率分别为5.4%和5.5%,SAE相关停药率分别为1.7%和1.5%。
  • 既往完全缓解的肝细胞癌(HCC)患者中30%复发,新发HCC报告率为0.93%。

核心结论

  • 在西班牙真实世界大队列中,OMV/PTV/r+DSV和LDV/SOF取得高SVR12率,与随机对照试验中观察到的相当,安全性特征同样良好。

研究设计与样本

  • 西班牙35个中心2015年4月1日至2016年2月28日期间1型HCV感染患者的大型国家数据库记录,接受OMV/PTV/r+DSV±RBV(n=1567)或LDV/SOF±RBV(n=1758)治疗。
  • 两个队列基线特征不匹配,无法直接比较。

主要发现

  • OMV/PTVr/DSV±RBV的SVR12率为96.8%,LDV/SOF±RBV为95.8%。
  • SVR率按HCV亚基因型无显著差异(p=0.321 [OMV/PTV/r+DSV±RBV]和p=0.174 [LDV/SOF]),按纤维化程度亦无显著差异(c0.548 [OMV/PTV/r/DSV±RBV]和p=0.085 [LDV/SOF])。
  • 多因素分析中仅基线白蛋白水平与未达到SVR显著相关(p<0.05)。
  • OMV/PTV/r+DSV亚队列SAE率和SAE相关治疗停药率分别为5.4%和1.7%,LDV/SOF亚队列分别为5.5%和1.5%。
  • 既往HCC治疗完全缓解的患者中30%出现HCC复发,新发HCC报告率为0.93%。

局限性

  • 两个队列基线特征不匹配,无法直接比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Clinical trials evaluating second-generation direct-acting antiviral agents (DAAs) have shown excellent rates of sustained virologic response (SVR) and good safety profiles in patients with chronic hepatitis C virus (HCV) genotype 1 infection. We aimed to investigate the effectiveness and safety of two oral DAA combination regimens, ombitasvir/paritaprevir/ritonavir plus dasabuvir (OMV/PTV/r+DSV) and ledipasvir/sofosbuvir (LDV/SOF), in a real-world clinical practice. METHODS: Data from HCV genotype 1 patients treated with either OMV/PTV/r+DSV±ribavirin (RBV) (n=1567) or LDV/SOF±RBV (n=1758) in 35 centers across Spain between April 1, 2015 and February 28, 2016 were recorded in a large national database. Demographic, clinical and virological data were analyzed. Details of serious adverse events (SAEs) were recorded. RESULTS: The two cohorts were not matched with respect to baseline characteristics and could not be compared directly. The SVR12 rate was 96.8% with OMV/PTVr/DSV±RBV and 95.8% with LDV/SOF±RBV. No significant differences were observed in SVR according to HCV subgenotype (p=0.321 [OMV/PTV/r+DSV±RBV] and p=0.174 [LDV/SOF]) or degree of fibrosis (c0.548 [OMV/PTV/r/DSV±RBV] and p=0.085 [LDV/SOF]). Only baseline albumin level was significantly associated with failure to achieve SVR (p<0.05) on multivariate analysis. Rates of SAEs and SAE-associated treatment discontinuation were 5.4% and 1.7%, in the OMV/PTV/r+DSV subcohort and 5.5% and 1.5% in the LDV/SOF subcohort, respectively. Hepatocellular carcinoma (HCC) recurred in 30% of patients with a complete response to therapy for previous HCC. Incident HCC was reported in 0.93%. CONCLUSIONS: In this large cohort of patients managed in the real-world setting in Spain, OMV/PTV/r+DSV and LDV/SOF achieved high rates of SVR12, comparable to those observed in randomized controlled trials, with similarly good safety profiles. LAY SUMMARY: In clinical trials, second-generation direct-acting antiviral agents (DAAs) have been shown to cure over 90% of patients chronically infected with the genotype 1 hepatitis C virus and have been better tolerated than previous treatment regimens. However, patients enrolled in clinical trials do not reflect the real patient population encountered in routine practice. The current study, which includes almost 4,000 patients, demonstrates comparable rates of cure with two increasingly used DAA combinations as those observed in the clinical trial environment, confirming that clinical trial findings with DAAs translate into the real-world setting, where patient populations are more diverse and complex.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Calleja JL, Crespo J, Rincón D, et al. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort. J Hepatol. 2017. PMID: 28189751. doi:10.1016/j.jhep.2017.01.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。